Recro Pharma Reports Fourth Quarter and Full Year 2014 Financial Results
March 25, 2015 08:00 ET
|
Societal CDMO, Inc.
‒ On Track to Report Top-Line Phase II Data from Dex-IN Post Op Day 1 Trial in Mid 2015 ‒
‒ Strengthened Company with Expected Acquisition of Phase III-Ready IV/IM Meloxicam,...
Recro Pharma to Acquire IV/IM Meloxicam and Gainesville, GA GMP Manufacturing Facility and Business Unit From Alkermes
March 09, 2015 06:00 ET
|
Societal CDMO, Inc.
- Transformative Acquisition Diversifies Recro Pharma's Development Risk with Second, Complementary Acute Pain Product
- Phase III-Ready, Long-Acting Injectable Meloxicam Has...
Recro Pharma Enters Into Common Stock Purchase Agreement With Aspire Capital
February 03, 2015 08:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post...
Recro Pharma to Present at the 17th Annual BIO CEO & Investor Conference
February 02, 2015 16:22 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post...
Recro Pharma Reports Third Quarter 2014 Financial Results
November 10, 2014 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
October 29, 2014 16:05 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference
September 08, 2014 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
September 04, 2014 16:51 ET
|
Societal CDMO, Inc.
Analgesia in a subset of patients (50%), suggests therapeutic potential for Dex-IN in Post Op Day 1
Trial not expected to reach statistical significance as single agent on Post Op Day 0...
Recro Pharma Reports Second Quarter 2014 Financial Results
August 12, 2014 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
Recro Pharma Added to Russell Microcap(R) Index
June 30, 2014 07:00 ET
|
Societal CDMO, Inc.
MALVERN, Pa., June 30, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...